title: Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.
abstract: OSU03012 is a non-COX inhibiting celecoxib derivative with growth inhibiting and apoptotic activity in many cancer cell lines. To investigate mechanisms related to cell cycle proteins in growth inhibition and apoptosis induced by OSU03012, the primary human oral epithelial cell line, TE1177, was transformed with HPV16 E6 (TE/E6), HPV16 E7 (TE/E7) or empty vector (TE/V). TE/E6 cell lines exhibiting low levels of p53 and undetectable levels of p21(WAF1/CIP1) were sensitized to the growth inhibiting and apoptotic effects of OSU03012. The TE/E7 cell lines expressing low levels of Rb and elevated levels of p53 and p21(WAF1/CIP1) were resistant. OSU03012 reduced the number of cells in the S phase of the TE/E7 and TE/V cell lines with intact p53-p21(WAF1/CIP1) checkpoint, but not in the checkpoint defective TE/E6 cell lines. Treatment with OSU03012 also markedly reduced the levels of cyclin A and Cdk2 in TE/E7 and TE/V, but not in TE/E6 cell lines, which had significantly enhanced basal levels of cyclin A and Cdk2. Consistent with the TE/E6 cell line, p21(WAF1/CIP1)-/- mouse embryo fibroblasts were more sensitive to OSU03012-induced apoptosis as evidenced by PARP and caspase 3 cleavages. These data suggest that p21(WAF1/CIP1) is an important factor in the sensitivity of cells to the growth inhibiting and apoptotic effects of OSU03012.
authors.affiliation: Department of Radiology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. ding.29@osu.edu
authors.forename: Haiming
authors.initials: H
authors.lastname: Ding
authors.forename: Chunhua
authors.initials: C
authors.lastname: Han
authors.forename: Dongmei
authors.initials: D
authors.lastname: Guo
authors.forename: Dasheng
authors.initials: D
authors.lastname: Wang
authors.forename: Wenrui
authors.initials: W
authors.lastname: Duan
authors.forename: Ching-Shih
authors.initials: CS
authors.lastname: Chen
authors.forename: Steven M
authors.initials: SM
authors.lastname: D'Ambrosio
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000187:drug effects / Q000378:metabolism; D015153:Blotting, Western; D001973:Bromodeoxyuridine / Q000378:metabolism; D002460:Cell Line; D019925:Cyclin A / Q000187:drug effects / Q000378:metabolism; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism*; D004622:Embryo, Mammalian; D005347:Fibroblasts / Q000187:drug effects; D005434:Flow Cytometry; D016193:G1 Phase / Q000187:drug effects; D020868:Gene Silencing; D006801:Humans; D047468:Immunoprecipitation; D051379:Mice; D009061:Mouth Mucosa / Q000166:cytology / Q000187:drug effects* / Q000821:virology; D009856:Oncogene Proteins, Viral / Q000187:drug effects / Q000378:metabolism; D027383:Papillomaviridae; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D012097:Repressor Proteins / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*; D014412:Tumor Virus Infections / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C438378:BBC3 protein, human; D019925:Cyclin A; D050759:Cyclin-Dependent Kinase Inhibitor p21; C068651:E6 protein, Human papillomavirus type 16; C500894:OSU 03012; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011518:Proto-Oncogene Proteins; D011720:Pyrazoles; D012097:Repressor Proteins; D013449:Sulfonamides; C059731:oncogene protein E7, Human papillomavirus type 16; D001973:Bromodeoxyuridine
references.citation: Int J Cancer. 2008 Dec 15;123(12):2923-30
references.pmid: 18798257
references.citation: Mol Pharmacol. 2007 Nov;72(5):1124-31
references.pmid: 17673571
references.citation: J Gastrointest Surg. 2006 Feb;10(2):207-14
references.pmid: 16455452
references.citation: J Oral Pathol Med. 1998 Sep;27(8):367-75
references.pmid: 9736425
references.citation: Cancer Res. 2004 Jun 15;64(12):4309-18
references.pmid: 15205346
references.citation: J Virol. 2004 Apr;78(8):4063-73
references.pmid: 15047823
references.citation: Nat Clin Pract Oncol. 2008 Jan;5(1):24-31
references.pmid: 18097454
references.citation: Mol Biol Cell. 2006 Jan;17(1):402-12
references.pmid: 16280359
references.citation: Int J Cancer. 1997 Aug 22;74(4):383-9
references.pmid: 9291426
references.citation: Cancer Res. 2005 May 15;65(10):3980-5
references.pmid: 15899785
references.citation: Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):597-603
references.pmid: 9681528
references.citation: Carcinogenesis. 2002 Aug;23(8):1289-96
references.pmid: 12151346
references.citation: Mol Pharmacol. 2008 Apr;73(4):1168-84
references.pmid: 18182481
references.citation: Anticancer Res. 2000 Jul-Aug;20(4):2273-80
references.pmid: 10953285
references.citation: Cancer Lett. 2005 Jan 20;217(2):129-38
references.pmid: 15617830
references.citation: Laryngoscope. 2007 Dec;117(12):2115-28
references.pmid: 17891052
references.citation: J Cell Biochem. 1995 Jun;58(2):151-9
references.pmid: 7673323
references.citation: Mol Cancer Ther. 2008 Apr;7(4):800-8
references.pmid: 18413793
references.citation: Nutr Cancer. 2005;51(2):207-17
references.pmid: 15860443
references.citation: Int J Cancer. 2003 Dec 10;107(5):830-6
references.pmid: 14566835
references.citation: Eur J Cancer B Oral Oncol. 1994 Sep;30B(5):338-45
references.pmid: 7703804
references.citation: J Virol. 2003 Jul;77(13):7291-9
references.pmid: 12805427
references.citation: Oncogene. 1998 Feb 12;16(6):705-12
references.pmid: 9488034
references.citation: Cell Cycle. 2003 Sep-Oct;2(5):438-41
references.pmid: 12963837
references.citation: Cancer Res. 2006 Dec 1;66(23):11254-62
references.pmid: 17145870
references.citation: J Oral Pathol Med. 2000 Oct;29(9):413-25
references.pmid: 11016683
references.citation: Clin Cancer Res. 2004 Mar 1;10(5):1813-25
references.pmid: 15014036
references.citation: Cancer Res. 2007 Apr 15;67(8):3801-8
references.pmid: 17440094
references.citation: Cell Biol Toxicol. 1997 Oct;13(6):419-34
references.pmid: 9352120
references.citation: Exp Cell Res. 2006 Apr 15;312(7):951-61
references.pmid: 16516887
references.citation: Mol Pharmacol. 2006 Aug;70(2):589-603
references.pmid: 16622074
references.citation: Lung Cancer. 2006 Apr;52(1):117-24
references.pmid: 16497409
references.citation: Proc Natl Acad Sci U S A. 1990 Feb;87(4):1268-72
references.pmid: 2406716
references.citation: Blood. 2005 May 15;105(10):4021-7
references.pmid: 15665113
references.citation: Trends Cell Biol. 2003 Feb;13(2):65-70
references.pmid: 12559756
references.citation: Mol Cancer Ther. 2005 Feb;4(2):257-70
references.pmid: 15713897
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4750-8
references.pmid: 17699852
references.citation: Mol Pharmacol. 2006 Nov;70(5):1534-41
references.pmid: 16887935
references.citation: Toxicol Pathol. 2007 Jun;35(4):549-61
references.pmid: 17562488
references.citation: In Vitro Cell Dev Biol. 1986 Sep;22(9):529-34
references.pmid: 3759794
references.citation: Curr Opin Genet Dev. 2007 Feb;17(1):60-5
references.pmid: 17208431
references.citation: Adv Exp Med Biol. 2007;608:52-69
references.pmid: 17993232
references.citation: Cancer Res. 2004 Feb 15;64(4):1444-51
references.pmid: 14973075
references.citation: Breast Cancer Res. 2005;7(5):R796-807
references.pmid: 16168126
references.citation: Nature. 1993 Dec 16;366(6456):701-4
references.pmid: 8259214
references.citation: Anticancer Drugs. 1997 Nov;8(10):903-10
references.pmid: 9436633
references.citation: Nat Rev Cancer. 2008 Apr;8(4):253-67
references.pmid: 18354415